CAS:839712-12-8
839712-12-8
CAS号：839712-12-8
品名：卡利拉嗪3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
中文别名：卡利拉嗪
英文别名：Cariprazine;trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea;Cariprazine(USAN/INN);3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea;trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine;RGH188;UNII-F6RJL8B278;trans4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine;
分子式：C21H32Cl2N4O
分子量：427.411
精确质量：426.195
Psa：42.31
UNII号：F6RJL8B278
密度：1.2±0.1g/cm3
沸点：600.1±55.0°Cat760mmHg
闪点：316.7±31.5°C
折射率：1.595
储存条件：-20°C
蒸汽压：0.0±1.7mmHgat25°C
简介：Cariprazine(tradenameVraylar,previouslyknownasRGH-188)isanantipsychoticdrugdevelopedbyGedeonRichter.ItactsasaD2andD3receptorpartialagonist,withhighselectivitytowardstheD3receptor.PositivePhaseIIIstudyresultswerepublishedforschizophreniaandmaniainearly2012,andforbipolardisorderIdepressionfromaPhaseIItrialin2015.Actiononthedopaminergicsystemsmakesitalsopotentiallyusefulasanadd-ontherapyinmajordepressivedisorder;RightsarecurrentlyownedbyGedeonRichterandActavis.ThedrugreceivedFDAapprovalonSeptember17,2015.
G蛋白偶联受体&G蛋白
